Cargando…

Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?

Circulating tumor cells (CTCs) mediate dissemination of solid tumors and can be an early sign of disease progression. Moreover, they show a great potential in terms of non-invasive, longitudinal monitoring of cancer patients. CTCs have been extensively studied in breast cancer (BC) and were shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Topa, Justyna, Grešner, Peter, Żaczek, Anna J., Markiewicz, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770434/
https://www.ncbi.nlm.nih.gov/pubmed/35048186
http://dx.doi.org/10.1007/s00018-021-04064-6
_version_ 1784635371213029376
author Topa, Justyna
Grešner, Peter
Żaczek, Anna J.
Markiewicz, Aleksandra
author_facet Topa, Justyna
Grešner, Peter
Żaczek, Anna J.
Markiewicz, Aleksandra
author_sort Topa, Justyna
collection PubMed
description Circulating tumor cells (CTCs) mediate dissemination of solid tumors and can be an early sign of disease progression. Moreover, they show a great potential in terms of non-invasive, longitudinal monitoring of cancer patients. CTCs have been extensively studied in breast cancer (BC) and were shown to present a significant phenotypic plasticity connected with initiation of epithelial-mesenchymal transition (EMT). Apart from conferring malignant properties, EMT affects CTCs recovery rate, making a significant portion of CTCs from patients’ samples undetected. Wider application of methods and markers designed to isolate and identify mesenchymal CTCs is required to expand our knowledge about the clinical impact of mesenchymal CTCs. Therefore, here we provide a comprehensive review of clinical significance of mesenchymal CTCs in BC together with statistical analysis of previously published data, in which we assessed the suitability of a number of methods/markers used for isolation of CTCs with different EMT phenotypes, both in in vitro spike-in tests with BC cell lines, as well as clinical samples. Results of spiked-in cell lines indicate that, in general, methods not based on epithelial enrichment only, capture mesenchymal CTCs much more efficiently that CellSearch(®) (golden standard in CTCs detection), but at the same time are not much inferior to Cell Search(®), though large variation in recovery rates of added cells among the methods is observed. In clinical samples, where additional CTCs detection markers are needed, positive epithelial-based CTCs enrichment was the most efficient in isolating CTCs with mesenchymal features from non-metastatic BC patients. From the marker side, PI3K and VIM were contributing the most to detection of CTCs with mesenchymal features (in comparison to SNAIL) in non-metastatic and metastatic BC patients, respectively. However, additional data are needed for more robust identification of markers for efficient detection of CTCs with mesenchymal features. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00018-021-04064-6.
format Online
Article
Text
id pubmed-8770434
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-87704342022-02-02 Breast cancer circulating tumor cells with mesenchymal features—an unreachable target? Topa, Justyna Grešner, Peter Żaczek, Anna J. Markiewicz, Aleksandra Cell Mol Life Sci Review Circulating tumor cells (CTCs) mediate dissemination of solid tumors and can be an early sign of disease progression. Moreover, they show a great potential in terms of non-invasive, longitudinal monitoring of cancer patients. CTCs have been extensively studied in breast cancer (BC) and were shown to present a significant phenotypic plasticity connected with initiation of epithelial-mesenchymal transition (EMT). Apart from conferring malignant properties, EMT affects CTCs recovery rate, making a significant portion of CTCs from patients’ samples undetected. Wider application of methods and markers designed to isolate and identify mesenchymal CTCs is required to expand our knowledge about the clinical impact of mesenchymal CTCs. Therefore, here we provide a comprehensive review of clinical significance of mesenchymal CTCs in BC together with statistical analysis of previously published data, in which we assessed the suitability of a number of methods/markers used for isolation of CTCs with different EMT phenotypes, both in in vitro spike-in tests with BC cell lines, as well as clinical samples. Results of spiked-in cell lines indicate that, in general, methods not based on epithelial enrichment only, capture mesenchymal CTCs much more efficiently that CellSearch(®) (golden standard in CTCs detection), but at the same time are not much inferior to Cell Search(®), though large variation in recovery rates of added cells among the methods is observed. In clinical samples, where additional CTCs detection markers are needed, positive epithelial-based CTCs enrichment was the most efficient in isolating CTCs with mesenchymal features from non-metastatic BC patients. From the marker side, PI3K and VIM were contributing the most to detection of CTCs with mesenchymal features (in comparison to SNAIL) in non-metastatic and metastatic BC patients, respectively. However, additional data are needed for more robust identification of markers for efficient detection of CTCs with mesenchymal features. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00018-021-04064-6. Springer International Publishing 2022-01-20 2022 /pmc/articles/PMC8770434/ /pubmed/35048186 http://dx.doi.org/10.1007/s00018-021-04064-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Topa, Justyna
Grešner, Peter
Żaczek, Anna J.
Markiewicz, Aleksandra
Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?
title Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?
title_full Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?
title_fullStr Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?
title_full_unstemmed Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?
title_short Breast cancer circulating tumor cells with mesenchymal features—an unreachable target?
title_sort breast cancer circulating tumor cells with mesenchymal features—an unreachable target?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770434/
https://www.ncbi.nlm.nih.gov/pubmed/35048186
http://dx.doi.org/10.1007/s00018-021-04064-6
work_keys_str_mv AT topajustyna breastcancercirculatingtumorcellswithmesenchymalfeaturesanunreachabletarget
AT gresnerpeter breastcancercirculatingtumorcellswithmesenchymalfeaturesanunreachabletarget
AT zaczekannaj breastcancercirculatingtumorcellswithmesenchymalfeaturesanunreachabletarget
AT markiewiczaleksandra breastcancercirculatingtumorcellswithmesenchymalfeaturesanunreachabletarget